Paclitaxel/Taxol / miR-199 Cancer Research Results

PacT, Paclitaxel/Taxol: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



miR-199, miR-199: Click to Expand ⟱
Source:
Type:

MicroRNA-199 (miR-199) is a family of small non-coding RNAs comprising miR-199a and miR-199b, with mature strands including miR-199a-5p, miR-199a-3p, miR-199b-5p, and miR-199b-3p. These microRNAs regulate gene expression by binding target mRNAs and promoting transcript degradation or translational repression. In many cancers, miR-199 ↓ is the more commonly reported pattern, and restoration or miR-199 ↑ frequently suppresses proliferation, migration, invasion, epithelial-mesenchymal transition, tumour growth, and treatment resistance while promoting apoptosis. Reported downstream targets and pathways include HIF-1α, mTOR/RHEB, YAP1, ITGA3, PAK4/MEK/ERK, KRAS/AKT/ERK, IKKβ/NF-κB, and RGS17. However, miR-199 can have oncogenic effects in selected cancers, so its direction must be recorded according to tumour type, mature strand, specimen, and experimental context. Cancer review; Tumour-suppressive example.



Scientific Papers found: Click to Expand⟱
6972- Form,  PacT,    Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy
- in-vivo, BC, MDA-MB-231
AntiCan↑, miR-199↓, ChemoSen↑, TumVol↓, Dose↝, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↓, eff↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

miR-199↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   TumVol↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: miR-199, miR-199
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:1543  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page